Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Net Margin (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Net Margin data on record, last reported at 126.37% in Q4 2025.

  • For Q4 2025, Net Margin fell 4492.0% year-over-year to 126.37%; the TTM value through Dec 2025 reached 124.24%, down 2407.0%, while the annual FY2025 figure was 124.24%, 2407.0% down from the prior year.
  • Net Margin reached 126.37% in Q4 2025 per MRVI's latest filing, down from 108.23% in the prior quarter.
  • Across five years, Net Margin topped out at 64.85% in Q3 2021 and bottomed at 249.84% in Q3 2024.
  • Average Net Margin over 5 years is 31.27%, with a median of 19.96% recorded in 2023.
  • Peak YoY movement for Net Margin: crashed -22726bps in 2024, then surged 14161bps in 2025.
  • A 5-year view of Net Margin shows it stood at 55.64% in 2021, then fell by -23bps to 42.71% in 2022, then tumbled by -447bps to 148.34% in 2023, then soared by 45bps to 81.45% in 2024, then tumbled by -55bps to 126.37% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 126.37% in Q4 2025, 108.23% in Q3 2025, and 147.34% in Q2 2025.